newsfilter
← Latest News
GlobeNewswire·

Zogenix Provides Corporate Update and Reports First Quarter 2021 Financial Results

Continued positive momentum for U.S. launch of FINTEPLA® (fenfluramine) oral solution in Dravet syndrome, with total net product sales of $12.3 million and total revenue of $13.7 million in the first quarter, representing quarter-over-quarter incre